MRas
Oncology
DiscoveryActive
Key Facts
About Qubit Pharmaceuticals
Qubit Pharmaceuticals is a Paris-based, private biotech firm pioneering a quantum-aided drug discovery platform. The company integrates decades of computational chemistry research into its ATLAS platform, which uses quantum mechanics, AI, and hybrid HPC/quantum computing to generate and simulate novel drug candidates with high precision. With a team of over 60 experts and a pipeline of over 20 programs, Qubit is targeting historically undruggable targets in oncology and inflammation while actively seeking partnerships to expand its impact.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Mvasi (bevacizumab biosimilar) | Viatris | Approved |
| DRL-17822 | Dr. Reddy's Laboratories | Phase 2 |
| Biosimilar Portfolio | Zydus Lifesciences | Various |
| therascreen Solid Tumor | Qiagen | Commercial |
| GBR 830 | Glenmark Pharmaceuticals | Phase 1 |
| Bevacizumab Biosimilar | Glenmark Pharmaceuticals | Approved |
| Biosimilar (Bevacizumab) | Ipca Laboratories | Development |
| LockBody Platform Assets | Centessa Pharmaceuticals | Pre-clinical |
| Everolimus | Amneal Pharmaceuticals | Approved |
| Lenalidomide (Revlimid generic) | Amneal Pharmaceuticals | Approved |
| Alymsys (bevacizumab-maly) | Amneal Pharmaceuticals | Approved |
| Pemrydi RTU | Amneal Pharmaceuticals | Approved |